Literature DB >> 12160922

Determinants of discontinuation of new courses of antihypertensive medications.

Jean-Pierre Grégoire1, Jocelyne Moisan, Rémi Guibert, Antonio Ciampi, Alain Milot, Michel Gaudet, Isabelle Côté.   

Abstract

Discontinuation of medication use constitutes a major barrier to adequate control of high blood pressure. We examined the effect of an array of potential predisposing, enabling and reinforcing factors on the discontinuation of newly prescribed antihypertensive medications. We conducted a prospective cohort study through a network of 173 pharmacies across Canada where were identified individuals newly prescribed an antihypertensive monotherapy. We interviewed participants by telephone four times to obtain information for a minimum duration of 18 months after entry into the cohort. We analyzed data using a multivariate proportional hazard model. Of 682 eligible participants, 43.3% had discontinued their initial medication at the end of the observation period. Individuals more likely to discontinue their initial medication were those who perceived side effects from this medication [Hazard Ratio (HR) = 1.91; 95% Confidence Interval (CI) 1.47-2.47). Individuals with medication insurance coverage were less likely to discontinue (HR = 0.74; 95% CI 0.55-0.99). Persistence with newly prescribed medications could be improved by selecting antihypertensive medications containing fewer side effects and by lifting economic barriers to drug treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12160922     DOI: 10.1016/s0895-4356(02)00400-6

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  24 in total

1.  Factors associated with the appropriate use of asthma drugs.

Authors:  Marie-Sophie Jobin; Jocelyne Moisan; Yves Bolduc; Eileen Dorval; Louis-Philippe Boulet; Jean-Pierre Grégoire
Journal:  Can Respir J       Date:  2011 Mar-Apr       Impact factor: 2.409

2.  Long-term adherence to evidence based secondary prevention therapies after acute myocardial infarction.

Authors:  Ayse Akincigil; John R Bowblis; Carrie Levin; Saira Jan; Minalkumar Patel; Stephen Crystal
Journal:  J Gen Intern Med       Date:  2007-10-06       Impact factor: 5.128

3.  Cardiovascular-related healthcare resource utilization and costs in patients with hypertension switching from metoprolol to nebivolol.

Authors:  Stephanie Chen; An-Chen Fu; Rahul Jain; Hiangkiat Tan
Journal:  Am Health Drug Benefits       Date:  2015-04

4.  Predictors of self-reported noncompliance with antihypertensive drug treatment: a prospective cohort study.

Authors:  J Grégoire; Jocelyne Moisan; Remi Guibert; Antonio Ciampi; Alain Milot
Journal:  Can J Cardiol       Date:  2006-03-15       Impact factor: 5.223

5.  Adherence to antihypertensive medications among family practice patients with diabetes mellitus and hypertension.

Authors:  Nandini Natarajan; Wayne Putnam; Kristine Van Aarsen; Kristine Beverley Lawson; Fred Burge
Journal:  Can Fam Physician       Date:  2013-02       Impact factor: 3.275

6.  Patient centered primary care is associated with patient hypertension medication adherence.

Authors:  Christianne L Roumie; Robert Greevy; Kenneth A Wallston; Tom A Elasy; Lisa Kaltenbach; Kristen Kotter; Robert S Dittus; Theodore Speroff
Journal:  J Behav Med       Date:  2010-12-16

7.  Using primary care prescribing databases for pharmacovigilance.

Authors:  Isa Naina Mohamed; Peter J Helms; Colin R Simpson; Robert M Milne; James S McLay
Journal:  Br J Clin Pharmacol       Date:  2011-02       Impact factor: 4.335

8.  Family practice patients' adherence to statin medications.

Authors:  Nandini Natarajan; R Wayne Putnam; Alexandra M Yip; Dawn Frail
Journal:  Can Fam Physician       Date:  2007-12       Impact factor: 3.275

9.  Drug Side Effect Symptoms and Adherence to Antihypertensive Medication.

Authors:  Yacob G Tedla; Leonelo E Bautista
Journal:  Am J Hypertens       Date:  2015-12-07       Impact factor: 2.689

10.  Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension.

Authors:  William B White; Robert Bresalier; Allen P Kaplan; Biff F Palmer; Robert H Riddell; Anastasia Lesogor; William Chang; Deborah L Keefe
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-10       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.